Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

CorMedix's $222.6M Heron Deal Buys a Four-Product Hospital Pain and Nausea Portfolio

CorMedix will acquire substantially all of Heron Therapeutics' assets, a hospital-focused portfolio, as small-cap biotechs elsewhere sell assets, license in or seek buyers.

15 Nov 2026 · CompePharma editorial

What happened

CorMedix has agreed to buy substantially all of Heron Therapeutics' assets in a deal worth about $222.6M upfront. The package includes four hospital-use products for postoperative pain and for nausea and vomiting. Closing is expected in the first quarter of 2027.

The structure matters. This is an asset purchase, not a merger of equals or a tender for shares. CorMedix takes the commercial portfolio, and the Heron corporate entity is left to be dealt with separately. The material we have does not say what happens to that entity, whether further consideration beyond the upfront payment is due, or how CorMedix will fund the purchase. Those gaps will shape how the deal is judged once filings land.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →